Literature DB >> 6821856

The prognostic significance of soft tissue extension in Ewing's sarcoma.

C M Mendenhall, R B Marcus, W F Enneking, D S Springfield, T L Thar, R R Million.   

Abstract

From January 1969 through December 1977, 28 patients were treated at the University of Florida with the diagnosis of Ewing's sarcoma. All patients received radiation therapy to the primary site and adjuvant chemotherapy according to several different regimens. A retrospective analysis was carried out to determine the prognostic significance of gross extraosseous extension by the primary lesion. Gross soft tissue extension at the primary site was found to be of prognostic importance. Patients with soft tissue extension more often presented with metastatic disease (39 versus 10%). The five-year survival rate for patients presenting without distant metastasis and whose primary lesions were grossly confined to bone was 87% compared to 20% for those with extraosseous extension. The decrease in survival with soft tissue extension resulted from an increase in distant metastasis as well as local failure, and was independent of primary site location. The proportion of patients with extraosseous extension should be reported in subsequent analyses of local control and survival.

Entities:  

Mesh:

Year:  1983        PMID: 6821856     DOI: 10.1002/1097-0142(19830301)51:5<913::aid-cncr2820510525>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  (Sub)periosteal Ewing's sarcoma of bone.

Authors:  P Wuisman; A Roessner; S Blasius; R Erlemann; W Winkelmann; J Ritter
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents.

Authors:  V Göbel; H Jürgens; G Etspüler; H Kemperdick; R M Jungblut; U Stienen; U Göbel
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Primary Ewing's sarcoma of the skull: follow-up with bone scanning.

Authors:  A Yildizhan; F Gezen
Journal:  Neurosurg Rev       Date:  1992       Impact factor: 3.042

4.  Local therapy of rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma of children and adolescents.

Authors:  G Prindull; H G Willert; G Notter
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

5.  Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging.

Authors:  H J van der Woude; J L Bloem; H C Holscher; M A Nooy; A H Taminiau; J Hermans; T H Falke; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

6.  Ewing's sarcoma. A retrospective study of histological and immunohistochemical factors and their relation to prognosis.

Authors:  S Daugaard; C Kamby; L M Sunde; O Myhre-Jensen; T Schiødt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

7.  Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations. A retrospective study of 261 cases.

Authors:  A Llombart-Bosch; G Contesso; M Henry-Amar; M J Lacombe; O Oberlin; J Dubousset; J Rouëssé; D Sarrazin
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

8.  Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study).

Authors:  O Oberlin; M C Deley; B N Bui; J C Gentet; T Philip; P Terrier; C Carrie; F Mechinaud; C Schmitt; A Babin-Boillettot; J Michon
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

9.  Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis.

Authors:  A Abudu; D C Mangham; G M Reynolds; P B Pynsent; R M Tillman; S R Carter; R J Grimer
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

10.  Localized Ewing sarcoma of the tibia.

Authors:  Takeshi G Kashima; Nimali G Gamage; Uta Dirksen; Christopher Lmh Gibbons; Simon J Ostlere; Nicholas A Athanasou
Journal:  Clin Sarcoma Res       Date:  2013-02-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.